Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs Carnival Corp (CCL) Price & Performance

BioNano Genomics IncTrade
Carnival CorpTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs Carnival Corp — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Carnival Corp trades at $26.53 (market cap $36.30B). The key difference: Carnival Corp is far larger — about 2750× BioNano Genomics Inc's market cap, and Carnival Corp pays a 1.7% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.

BNGOCCL
Market Cap
$13.20M$36.30B
Sector
HealthConsumer Cyclical
52-Week High
$4.92$33.99
52-Week Low
$1.09$23.89
Enterprise Value
$15.81M$60.22B
Dividend Yield
1.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.

BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.

Carnival Corp

Carnival Corporation (CCL) trades at $26.61, down 0.82% on the day, amid a bearish technical signal. The company demonstrates strong fundamental improvement with revenue growth to $26.62 billion in 2025 and net income of $2.76 billion, supported by three consecutive quarterly EPS beats. Positive analyst sentiment is evident with a $35.00 consensus price target and 59.57% buy ratings, while recent news highlights fleet expansion and strong bookings.

The outlook remains positive due to robust demand and cost controls, but risks include geopolitical tensions impacting fuel costs and softer European demand. The stock's current valuation metrics, such as a P/E of 11.99, suggest potential upside if execution continues, though investors must weigh debt levels and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About Carnival Corp

Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.

Read more on CCL